How to Value Healthcare and Biotech Stocks

By Nazli Hangeldiyeva

Healthcare is the only sector where a single binary event, an FDA approval or rejection, can double or halve a company's value overnight. When Biogen's Alzheimer's drug Leqembi received traditional FDA approval in 2023, the stock jumped 40%. When Intercept Pharmaceuticals' liver disease drug was rejected by an FDA advisory committee in 2023, the stock fell 50% in after-hours trading. This event-driven volatility makes healthcare one of the most challenging and potentially rewarding sectors for fundamental analysis.

The sector spans an enormous range of business models: large-cap pharmaceutical companies with diversified drug portfolios and stable cash flows, clinical-stage biotechs with no revenue and a single drug candidate, medical device manufacturers with recurring revenue from consumables, managed care organizations that function as insurance companies, and healthcare IT firms that resemble software businesses. Each requires a tailored valuation approach, and applying the wrong framework to the wrong company type produces unreliable results.

Large-Cap Pharmaceutical Companies

Companies like Pfizer, Johnson & Johnson, AbbVie, and Eli Lilly have diversified portfolios of approved drugs generating tens of billions in annual revenue. They are mature, cash-generative businesses that can be valued using traditional methods, with one critical modification: the patent cliff.

Patent cliff analysis. Every branded drug has a finite exclusivity period. When a key patent expires, generic competition enters and revenue from that drug can decline 80-90% within two years. AbbVie's Humira, which generated $21 billion in annual peak revenue, faced U.S. biosimilar competition starting in 2023. Modeling the revenue decline curve for each major product is a required step in pharma valuation.

To value a large pharma company:

1. Project revenue for each major product individually, incorporating patent expiration dates, competitive entry, and lifecycle management (new formulations, expanded indications)
2. Model the contribution from the pipeline (new drugs in development), probability-weighted by stage of development
3. Estimate operating margins, adjusting for the transition from high-margin patented products to lower-margin portfolio mix
4. Build a standard DCF or comparable company analysis using these projections

Typical multiples. Large pharma companies trade at 12-18x forward earnings, a discount to the S&P 500 reflecting patent risk and regulatory uncertainty. Companies with strong pipelines and minimal near-term patent cliffs (Eli Lilly, with its obesity and diabetes franchise) trade at the high end. Those with significant patent cliffs and thin pipelines trade at the low end.

Clinical-Stage Biotech: Risk-Adjusted NPV

Clinical-stage biotechs have no approved products and no revenue. Their value lies entirely in the drugs they are developing, which may or may not work. The standard valuation method is risk-adjusted net present value (rNPV).

The rNPV framework:

1. Estimate peak sales. For each drug candidate, project peak annual revenue based on the target disease's prevalence, expected market share, pricing assumptions, and competitive dynamics. An oncology drug targeting a rare cancer might have peak sales of $500 million. A diabetes drug targeting a massive patient population might reach $10 billion.

2. Build a revenue curve. Drug revenues follow a characteristic pattern: a 3-5 year ramp to peak sales, a plateau period, and a decline as patent expiration approaches. The entire curve, from launch to loss of exclusivity, typically spans 10-15 years.

3. Apply the probability of success. Each stage of clinical development has a historical probability of success:

A Phase 2 drug with estimated peak sales of $2 billion and a 20% probability of reaching the market has probability-adjusted peak sales of $400 million. These probabilities vary by therapeutic area: oncology has lower success rates than cardiovascular, and rare diseases have higher rates than common conditions.

4. Project costs. Estimate the remaining development costs (clinical trial expenses, regulatory filing fees) and the cost to commercialize (sales force, manufacturing). Phase 3 trials can cost $100 million to $1 billion depending on the disease, trial size, and endpoints.

5. Discount the net cash flows. Use a discount rate of 10-15%, higher than for established companies to reflect the additional risk. Sum the discounted, probability-adjusted cash flows across all pipeline assets and subtract the company's cash burn and debt. Add current cash on the balance sheet.

The result is a per-share rNPV that represents the expected value of the pipeline given the probabilities and assumptions. If the stock trades below this value, the market is pricing in more pessimism than the data supports (or the analyst's assumptions are too aggressive).

Medical Device Companies

Medical device companies like Medtronic, Stryker, Abbott Laboratories, and Boston Scientific occupy a middle ground between pharma and industrial companies. They manufacture physical products (implants, surgical instruments, diagnostic equipment, consumables) that are used in medical procedures.

Recurring revenue from consumables. Device companies with a razor-and-blade model, where the initial device is sold at a moderate margin and high-margin consumables generate recurring revenue, command premium valuations. Abbott's continuous glucose monitoring (CGM) franchise generates billions in recurring sensor revenue from patients who use a new sensor every 14 days.

Procedure volume growth. Revenue growth is driven by the number of procedures performed (a function of demographics, disease prevalence, and insurance coverage) and the company's market share within those procedures. An aging population increases demand for orthopedic implants, cardiac devices, and diagnostic procedures.

EV/EBITDA and P/E. Medical device companies typically trade at 18-25x forward earnings, reflecting high margins (50%+ gross margins are common), recurring revenue characteristics, and defensive demand. Stryker and Intuitive Surgical, with strong growth and market-leading positions, have traded at premium multiples above 30x.

Regulatory and reimbursement risk. FDA approval and insurance reimbursement rates are gatekeepers for device revenue. A new device that receives FDA clearance but inadequate Medicare reimbursement will underperform commercially. Analysts must monitor reimbursement decisions from CMS (Centers for Medicare & Medicaid Services) as closely as they monitor FDA actions.

Managed Care and Health Insurance

Managed care organizations (MCOs) like UnitedHealth Group, Elevance Health, Cigna, and Humana are insurance companies that also operate healthcare services. They collect premiums and pay medical claims.

Medical loss ratio (MLR). The percentage of premiums paid out as medical claims. An MLR of 82% means the insurer retains 18% of premiums for administration, profits, and reserves. The Affordable Care Act mandates minimum MLR thresholds (80% for individual and small group, 85% for large group), capping the amount insurers can retain. A rising MLR indicates higher medical costs relative to premiums and compresses profitability.

Membership growth. The number of insured members drives revenue scale. Membership growth comes from winning employer contracts, expanding Medicaid managed care, and growing Medicare Advantage enrollment. UnitedHealth's Medicare Advantage membership growth has been a primary valuation driver.

P/E and PEG ratio. MCOs are valued on earnings multiples, typically 15-20x forward earnings. Growth-oriented MCOs with expanding membership and strong cost management trade at premiums. UnitedHealth has consistently traded at a premium to peers, reflecting its Optum health services division, which adds diversification beyond insurance.

Valuation Considerations Across Healthcare

Patent and exclusivity dynamics. Unlike most assets, drug revenue has an expiration date. All valuations must account for when key products lose exclusivity and how quickly generic or biosimilar competition erodes revenue.

Regulatory binary events. FDA approval decisions, advisory committee votes, and complete response letters (rejections) create step-function changes in value. For companies dependent on a single drug candidate, these events dominate the valuation. Informed investors track FDA action dates (PDUFA dates) and advisory committee schedules.

Pricing and political risk. Drug pricing is a perennial political issue in the United States. The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for the first time, directly affecting the revenue trajectory of selected drugs. Future legislative changes could expand price controls. Valuation models should incorporate scenarios for pricing pressure on high-revenue drugs.

Pipeline optionality. For large pharma and established biotech companies, pipeline drugs represent options on future revenue streams. A Phase 1 asset has limited near-term value but could become a multi-billion-dollar product in 8-10 years. Analysts often assign nominal value to early-stage pipeline assets and increase the assigned value as drugs progress through clinical development.

M&A activity. Healthcare is one of the most active sectors for M&A, and the threat (or hope) of acquisition affects valuations. Large pharma companies with patent cliffs are serial acquirers of biotech companies with promising pipelines. AbbVie's $63 billion acquisition of Allergan, Pfizer's $43 billion acquisition of Seagen, and Bristol-Myers Squibb's $74 billion acquisition of Celgene were all driven by the need to replace lost revenue from patent expirations. Clinical-stage biotechs with differentiated drugs in Phase 2 or Phase 3 development are the most common acquisition targets.

The healthcare sector rewards deep specialization. An analyst who understands clinical trial design, FDA regulatory pathways, patent law, and insurance reimbursement mechanisms has a significant informational advantage. The complexity that deters many investors is the same complexity that creates mispricing opportunities for those willing to do the work.

Written by

Nazli Hangeldiyeva

Co-Founder of Grid Oasis. Political Science & International Relations, Istanbul Medipol University.

View full profile →